News detailing the first patient dosed in a clinical trial for AXT107 led retina coverage in the beginning of January.
Read the rest of the top-performing retina articles below.
First patient dosed in AXT107 clinical trial for DME
The first patient has been dosed in a phase 1/2a clinical trial of AXT107 to evaluate the safety and bioactivity of the therapy in patients with diabetic macular edema. Read more.
Notal Vision initiates study investigating at-home OCT monitoring of AMD
Notal Vision has initiated a longitudinal study to evaluate the ability (Read more...)
Uncategorized